Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04624906
Title Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia (BRAWM)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sunnybrook Health Sciences Centre

Waldenstroem's macroglobulinemia


Acalabrutinib + Bendamustine + Rituximab

Age Groups: senior | adult
Covered Countries CAN

No variant requirements are available.